GEMP - Gemphire Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.2500
+0.3400 (+4.30%)
As of 10:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.9100
Open7.8700
Bid8.1700 x 1300
Ask8.1000 x 800
Day's Range7.8700 - 8.2500
52 Week Range4.7500 - 21.5900
Volume65,624
Avg. Volume403,687
Market Cap117.416M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.9920
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.40
Trade prices are not sourced from all markets
  • What’s behind Gemphire Therapeutics’ Stock Price Rise
    Market Realist11 days ago

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.

  • Why Gemphire Therapeutics Stock Is Rising Today
    Market Realist21 days ago

    Why Gemphire Therapeutics Stock Is Rising Today

    Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint of significantly reducing triglyceride levels in Severe Hypertriglyceridemia (or SHTG) patients with baseline serum triglyceride levels greater than 500 mg/dl. The drug also demonstrated a solid safety and tolerability profile and could be safely combined with other drugs. Gemcabene currently holds a method patent in SHTG indication valid until 2032. ...

  • Benzinga21 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...

  • Benzinga21 days ago

    Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...

  • ACCESSWIRE21 days ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.

  • GlobeNewswire22 days ago

    Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it achieved the primary endpoint, reduction of TGs by gemcabene, in its Phase 2b INDIGO-1 trial in SHTG patients with baseline serum TGs 500 mg/dL.

  • GlobeNewswire2 months ago

    Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and dyslipidemia, is sponsoring via an educational grant the American Liver Foundation’s (ALF) upcoming webinar "Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely Starts in Childhood” on Wednesday, May 23. The American Liver Foundation is a non-profit organization that facilitates, advocates, and promotes education, support, and research for the prevention, treatment, and cure of liver disease.

  • Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important
    Simply Wall St.2 months ago

    Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important

    I am going to take a deep dive into Gemphire Therapeutics Inc’s (NASDAQ:GEMP) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • GlobeNewswire2 months ago

    Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

    LIVONIA, Mich., May 08, 2018-- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic ...

  • GlobeNewswire3 months ago

    Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), today announced the appointment of Steven Gullans, Ph.D., as its President and Chief Executive Officer, effective immediately. Dr. Gullans has been Interim President and Chief Executive Officer since May 2017.  He has almost 30 years of experience advising, co-founding and investing in biotech companies across many fields including cardiovascular disease.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT

    Q4 2017 Gemphire Therapeutics Inc Earnings Call

  • Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?
    Simply Wall St.4 months ago

    Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?

    Gemphire Therapeutics Inc’s (NASDAQ:GEMP): Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitisRead More...

  • Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
    Zacks5 months ago

    Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?

    Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.

  • GuruFocus.com5 months ago

    Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ...

    Interim President & CEO of Gemphire Therapeutics Inc (NASDAQ:GEMP) Steven R. Ph.d. Gullans bought 71,429 shares of GEMP on 02/08/2018 at an average price of $7 a share.

  • What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?
    Simply Wall St.7 months ago

    What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?

    The latest earnings release Gemphire Therapeutics Inc’s (NASDAQ:GEMP) announced in September 2017 signalled that losses became smaller relative to the prrior year’s level – great news for investors Investors mayRead More...